文献速递哮喘

抗白介素-5治疗哮喘疗效与安全性的系统评价

[Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: systematic reviews].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2017-01-01

结果显示抗IL-5抗体可降低急性加重风险、改善FEV1及AQLQ评分,并降低不良事件风险,耐受性良好。

要点

  • 抗IL-5抗体降低哮喘急性加重风险(RR=0.66)。
  • 抗IL-5抗体改善FEV1、FEV1占预计值%及AQLQ评分。
  • 抗IL-5抗体不良事件风险低于安慰剂(OR=0.71)。

核心结论

  • 抗IL-5单克隆抗体可降低哮喘患者急性加重发生率并改善肺功能及生命质量,且耐受性良好。

主要发现

  • 抗IL-5单克隆抗体较安慰剂显著降低急性加重风险(RR=0.66,95%CI 0.59–0.73)。
  • 抗IL-5单克隆抗体较安慰剂改善FEV1(MD=0.10,95%CI 0.07–0.13)。
  • 抗IL-5单克隆抗体较安慰剂改善FEV1占预计值%(MD=3.90,95%CI 1.86–5.95)。
  • 抗IL-5单克隆抗体较安慰剂改善AQLQ评分(MD=0.24,95%CI 0.16–0.32)。
  • 抗IL-5单克隆抗体较安慰剂降低不良事件风险(OR=0.71,95%CI 0.58–0.87)。

临床怎么用

  • 对哮喘患者,抗IL-5单克隆抗体可作为降低急性加重风险、改善肺功能与生命质量的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of anti-Interleukin-5 therapy in patients with asthma. Methods: Data were collected from PubMed, E-Mbase, Springer, Ovid, Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database (-Feb 2017). Bibliographies of the retrieved articles were checked and analyzed. Results: Twenty publications involving a total of 6 406 patients were used in the analysis, including 23 randomly controlled trials (RCTs) which compared anti-interleukin 5 monoclonal antibody with placebo. Pooled analyses showed that anti-interleukin 5 monoclonal antibody significantly reduced exacerbation risk [RR=0.66, 95%CI(0.59, 0.73)], increased FEV(1)[MD=0.10, 95%CI(0.07, 0.13)] and FEV(1)% predicted [MD=3.90, 95%CI(1.86, 5.95)], and improved the scores on the Asthma Quality of Life Questionnaire (AQLQ) [MD=0.24, 95%CI(0.16, 0.32)]. Anti-interleukin 5 monoclonal antibody was also associated with significantly decreased risk of adverse events than placebo[OR=0.71, 95%CI(0.58, 0.87)]. Conclusion: Anti-interleukin 5 monoclonal antibody reduces the risk of exacerbations and improves quality of life in patients with asthma, and is tolerated well. 目的: 系统评价抗IL-5抗体治疗支气管哮喘(哮喘)患者的疗效及安全性。 方法: 根据特定中英文检索词检索PubMed、EMbase、Springer、Ovid、Cochrane Library、ClinicalTrials.gov和CNKI、万方数据库的所有相关临床随机对照研究(RCT),检索时间截至2017年2月。同时检索纳入文献的参考文献,并逐个进行质量评价和资料提取。采用RevMan5.3软件进行统计学分析。 结果: 共纳入20篇文献,23个RCT,共计6 406例患者。荟萃分析结果显示,抗IL-5抗体可明显降低哮喘急性加重的发生率[RR=0.66,95%CI(0.59,0.73)],改善患者FEV(1)[MD=0.10,95%CI(0.07,0.13)]、FEV(1)占预计值% [MD=3.90,95%CI(1.86,5.95)]和哮喘生命质量问卷(AQLQ)评分[MD=0.24,95%CI(0.16,0.32)],且降低了不良事件的发生风险[OR=0.71,95%CI(0.58,0.87)]。 结论: 抗IL-5抗体可降低哮喘患者急性加重的发生率,并改善患者肺功能及生命质量,且具有较好的耐受性。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gu YL, Pang J, Song JF, et al. [Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: systematic reviews]. Zhonghua Jie He He Hu Xi Za Zhi. 2017. PMID: 29320831. doi:10.3760/cma.j.issn.1001-0939.2017.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。